Medical School · Year 2 · Pharmacology · includes a quiz and discussion video

Lecture 02: Pharmacodynamics

Unit 2.12: Pharmacology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe drug-receptor interactions and receptor types
2. Explain dose-response relationships and curves
3. Describe agonists, antagonists, and partial agonists
4. Explain potency, efficacy, and therapeutic index
5. Describe receptor regulation and tolerance
6. Explain drug interactions and adverse drug reactions

Lecture Outline

I. Overview of Pharmacodynamics

Pharmacodynamics represents the complementary discipline to pharmacokinetics, focusing on what the drug does to the body rather than what the body does to the drug. This field examines the biochemical and physiological effects of drugs and their mechanisms of action at the molecular, cellular, and organ system levels. The fundamental relationship in pharmacodynamics follows the sequence of dose leading to concentration at the site of action, which then produces a measurable pharmacological effect. Understanding pharmacodynamic principles is essential for predicting drug effects, optimizing therapeutic outcomes, and anticipating adverse reactions in clinical practice.

Drug targets represent the molecular sites where drugs interact to produce their pharmacological effects, and these targets fall into several major categories. Receptors constitute the largest and most important class of drug targets, including G protein-coupled receptors, ligand-gated ion channels, and nuclear receptors that transduce extracellular signals into cellular responses. Enzymes serve as drug targets when their inhibition or activation produces therapeutic benefit, with examples including cyclooxygenase inhibited by NSAIDs, angiotensin-converting enzyme blocked by ACE inhibitors, and HMG-CoA reductase targeted by statins. Ion channels, transporters, and nucleic acids represent additional drug target classes, with voltage-gated channels blocked by antiarrhythmics, neurotransmitter transporters inhibited by antidepressants, and DNA targeted by antibiotics and chemotherapeutic agents.

Receptor theory provides the conceptual framework for understanding how drugs interact with their molecular targets to produce biological effects. A receptor is defined as a macromolecule, typically a protein, that specifically recognizes and binds drug molecules (ligands) to initiate a cascade of events leading to a cellular response. Drug-receptor binding may be reversible, allowing equilibrium between bound and unbound states, or irreversible when covalent bonds form between drug and receptor. The occupancy theory posits that the magnitude of drug effect is generally proportional to the fraction of receptors occupied, though this relationship is modified by concepts of receptor reserve and intrinsic activity.

Drug-receptor binding is characterized by several quantitative parameters that describe the strength and specificity of the interaction. Affinity refers to the strength of binding between a drug and its receptor, with higher affinity indicating tighter binding and lower concentrations needed for receptor occupation. The dissociation constant (Kd) quantifies affinity as the drug concentration at which 50% of receptors are occupied at equilibrium, with lower Kd values indicating higher affinity. Specificity describes whether a drug interacts with one particular target versus multiple targets, while selectivity refers to the relative affinity of a drug for different receptor subtypes, such as beta-1 versus beta-2 adrenergic receptors. These binding parameters directly influence drug dosing, therapeutic efficacy, and the potential for off-target effects.

<image>Panel A: Schematic showing the pharmacodynamic relationship from drug dose to plasma concentration to tissue concentration to receptor binding to pharmacological effect, with feedback loops and modulating factors indicated. Panel B: Diagram of major drug target classes showing cell membrane receptors (GPCR, ion channel), intracellular enzymes, membrane transporters, and nuclear receptors with representative drug examples for each. Panel C: Receptor occupancy theory illustration showing drug molecules (ligands) binding to receptors on cell surface, with equilibrium arrows between bound and unbound states and correlation to effect magnitude. Panel D: Affinity and selectivity comparison showing drug binding to primary target with high affinity (low Kd) versus off-target binding with low affinity (high Kd), demonstrating the basis for selective drug action.</image>

II. Receptor Types

G protein-coupled receptors (GPCRs) constitute the largest family of cell surface receptors and represent the most common drug targets in pharmacology. These receptors share a characteristic structure featuring seven transmembrane alpha-helical domains that span the plasma membrane, with an extracellular N-terminus and intracellular C-terminus. Upon ligand binding, GPCRs undergo conformational changes that activate associated heterotrimeric G proteins on the cytoplasmic face of the membrane, initiating intracellular signaling cascades. The response time for GPCR-mediated effects ranges from seconds to minutes, making them suitable for rapid physiological responses. Clinically important GPCRs include beta-adrenergic receptors targeted by beta-blockers, muscarinic acetylcholine receptors targeted by anticholinergics, and opioid receptors activated by analgesics.

GPCR signaling pathways are classified according to the type of G protein alpha subunit that couples to the receptor, with each type producing distinct cellular effects. Stimulatory G proteins (Gs) activate adenylyl cyclase, increasing intracellular cyclic AMP levels and subsequently activating protein kinase A; receptors coupled to Gs include beta-adrenergic receptors, dopamine D1 receptors, and histamine H2 receptors. Inhibitory G proteins (Gi) inhibit adenylyl cyclase, decreasing cAMP levels; examples include alpha-2 adrenergic receptors, muscarinic M2 receptors, and dopamine D2 receptors. The Gq family activates phospholipase C, generating the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG), leading to calcium release and protein kinase C activation; alpha-1 adrenergic, M1 and M3 muscarinic, and histamine H1 receptors couple through Gq.

Ligand-gated ion channels represent receptors that combine ligand recognition and ion conductance functions within a single macromolecular complex. These receptors respond to ligand binding by directly opening an ion-conducting pore through the plasma membrane, producing extremely rapid responses on the order of milliseconds. Nicotinic acetylcholine receptors at the neuromuscular junction are cation channels that depolarize muscle cells upon acetylcholine binding. GABA-A receptors are chloride channels that hyperpolarize neurons when activated, producing inhibitory effects that are enhanced by benzodiazepines and barbiturates. Glutamate receptors, including NMDA and AMPA subtypes, are excitatory cation channels critical for synaptic transmission and plasticity in the central nervous system.

Additional receptor families utilize distinct mechanisms to transduce extracellular signals into cellular responses over varying time scales. Receptor tyrosine kinases possess intrinsic enzymatic activity in their cytoplasmic domains and are activated by growth factors, insulin, and related hormones, with signaling occurring over minutes through phosphorylation cascades. Nuclear receptors, including those for steroid hormones, thyroid hormone, and vitamin D, are transcription factors that regulate gene expression, producing effects that develop over hours to days due to the requirement for protein synthesis. Cytokine receptors lack intrinsic kinase activity but associate with Janus kinases (JAK) that phosphorylate signal transducers and activators of transcription (STAT), mediating responses to interferons and interleukins. The diverse mechanisms and time courses of these receptor families account for the wide range of drug effects from immediate to delayed onset.

<image>Panel A: GPCR structure showing seven transmembrane domains threading through plasma membrane, extracellular ligand-binding domain, and intracellular coupling to heterotrimeric G protein with alpha, beta, and gamma subunits. Panel B: Comparison of three G protein signaling pathways showing Gs increasing cAMP via adenylyl cyclase, Gi decreasing cAMP, and Gq activating phospholipase C to generate IP3 and DAG, with downstream effectors and example receptors for each. Panel C: Ligand-gated ion channel showing nicotinic receptor pentameric structure, acetylcholine binding to extracellular domain, and central pore opening to allow cation influx causing membrane depolarization. Panel D: Comparison of receptor response times from fastest (ion channels, milliseconds) through GPCR (seconds-minutes) and receptor tyrosine kinase (minutes) to slowest (nuclear receptors, hours-days), with example drugs acting at each.</image>

III. Dose-Response Relationships

Graded dose-response relationships describe the progressive increase in drug effect as dose or concentration increases, fundamental to understanding drug action at the individual level. As drug concentration rises, more receptors become occupied, producing greater pharmacological effect until a maximum response is reached when all receptors are occupied or when the effector system becomes saturated. When plotted on semi-logarithmic axes with log concentration on the x-axis and effect on the y-axis, the dose-response curve assumes a characteristic sigmoidal shape with three distinct regions. The EC50 (effective concentration 50%) represents the concentration producing 50% of maximal effect and serves as a standard measure of drug potency. The Emax represents the maximum effect the drug can produce at saturating concentrations and reflects the drug's efficacy.

Quantal dose-response relationships differ from graded responses by measuring the proportion of a population that exhibits a defined all-or-none response at various doses. Rather than measuring the magnitude of effect in an individual, quantal analysis counts the fraction of subjects responding at each dose level, where the response is either present or absent. The ED50 (effective dose 50%) indicates the dose producing the defined therapeutic effect in 50% of the population and is used in clinical dosing guidelines. Similarly, TD50 represents the dose causing toxicity in 50% of subjects, while LD50 (lethal dose 50%) represents the dose that is lethal to 50% of subjects in preclinical testing. Quantal dose-response analysis is essential for determining population-based dosing recommendations and assessing drug safety margins.

Several characteristics of dose-response curves provide clinically useful information for comparing drugs and predicting their behavior. Potency refers to the position of the curve along the dose axis, with drugs having left-shifted curves (lower EC50) being more potent and requiring smaller doses to achieve the same effect. Efficacy corresponds to the maximum height of the curve (Emax) and indicates the ceiling of effect achievable regardless of dose. The slope of the dose-response curve indicates how rapidly effect changes with dose; steep curves mean small dose changes produce large effect changes, while shallow curves indicate more gradual dose-effect relationships. The threshold dose represents the minimum dose required to produce any detectable effect and is important for understanding the lower boundary of drug activity.

Logarithmic dose-response plotting offers several advantages over linear dose scales for pharmacological analysis. Because drug effects typically span wide concentration ranges from nanomolar to millimolar, logarithmic scaling compresses this range into a manageable axis that displays all relevant information. The sigmoidal shape that emerges on semi-logarithmic plots has a linear middle portion between approximately 20% and 80% of maximum effect, facilitating accurate determination of EC50. This standard presentation allows direct visual comparison of potency and efficacy between different drugs when plotted on the same axes. The shape of the log dose-response curve also provides mechanistic information, as it reflects the underlying receptor binding equilibrium and the relationship between receptor occupancy and effect.

<image>Panel A: Graded dose-response curve on semi-logarithmic axes showing sigmoidal shape with EC50 marked at 50% effect level, Emax indicated as plateau, threshold dose at curve onset, and slope indicated in the linear portion. Panel B: Quantal dose-response showing cumulative frequency distribution of population responding at each dose, with ED50, TD50, and LD50 marked on x-axis and percent responding (0-100%) on y-axis. Panel C: Comparison of two drugs showing drug A with lower EC50 (more potent) but same Emax as drug B, and drug C with same potency as drug A but lower Emax (less efficacious). Panel D: Logarithmic versus linear dose scaling showing how log scale compresses wide dose ranges and reveals sigmoidal curve character obscured on linear scale.</image>

IV. Agonists and Antagonists

Agonists are drugs that bind to receptors and activate them to produce a biological response, mimicking the action of endogenous ligands. Full agonists produce the maximum response that the receptor-effector system is capable of generating, with an intrinsic activity value of 1 representing complete activation. The concept of intrinsic activity quantifies the ability of a drug to activate a receptor relative to a standard full agonist, ranging from 0 (no activation) to 1 (full activation). Full agonists are clinically useful when maximum receptor activation is desired, such as opioid analgesics like morphine that fully activate mu-opioid receptors to produce analgesia. The dose-response curve of a full agonist reaches the same maximum effect as the endogenous ligand, though potency may differ.

Partial agonists bind to and activate receptors but cannot elicit the maximum response regardless of concentration, even when all receptors are occupied. These drugs have intrinsic activity values between 0 and 1, producing submaximal effect compared to full agonists acting at the same receptor. Partial agonists exhibit dual behavior: they act as agonists when administered alone but can function as antagonists when co-administered with full agonists by competing for receptor occupancy while producing lesser activation. Buprenorphine exemplifies a clinically important partial agonist, producing analgesia and treating opioid dependence while having a ceiling effect that limits respiratory depression compared to full opioid agonists. Inverse agonists represent a special category that bind to receptors and reduce constitutive (basal) activity below baseline, producing effects opposite to agonists at receptors with spontaneous activity.

Antagonists are drugs that bind to receptors without activating them, preventing or reducing the effect of agonists. Competitive antagonists bind reversibly to the same site as agonists (the orthosteric site), and their blockade can be overcome by increasing agonist concentration. On dose-response curves, competitive antagonists produce a rightward (parallel) shift in the agonist curve without reducing the maximum effect, since sufficient agonist can always displace the antagonist. Propranolol competitively blocks beta-adrenergic receptors, antagonizing the effects of epinephrine, but the antagonism can be surmounted by very high epinephrine concentrations. The degree of rightward shift depends on antagonist concentration and its affinity for the receptor.

Non-competitive antagonists reduce the maximum response achievable by agonists through mechanisms that cannot be overcome by increasing agonist concentration. These antagonists may bind to allosteric sites distinct from the agonist binding site, inducing conformational changes that impair receptor function. Alternatively, non-competitive antagonism may result from irreversible binding to the orthosteric site through covalent bond formation. Phenoxybenzamine is an irreversible alpha-adrenergic antagonist that covalently modifies the receptor, producing insurmountable antagonism useful in treating pheochromocytoma. On dose-response curves, non-competitive antagonists reduce the Emax while having variable effects on EC50, and the antagonism persists until new receptors are synthesized. Chemical antagonism, where one drug directly inactivates another without involving receptors, represents a distinct mechanism exemplified by protamine neutralizing heparin.

<image>Panel A: Receptor activation spectrum showing inverse agonist decreasing basal activity, neutral antagonist maintaining baseline, partial agonist producing submaximal activation, and full agonist achieving maximum response, with intrinsic activity values indicated. Panel B: Comparison of full agonist (morphine) and partial agonist (buprenorphine) dose-response curves at mu-opioid receptor, showing buprenorphine plateau at submaximal effect and its ability to reduce morphine response when co-administered. Panel C: Competitive antagonism diagram showing agonist and antagonist competing for same binding site, with dose-response curves demonstrating rightward parallel shift with preserved Emax at increasing antagonist concentrations. Panel D: Non-competitive antagonism showing irreversible antagonist (phenoxybenzamine) covalently binding receptor, reducing available receptors and decreasing Emax on dose-response curve regardless of agonist concentration.</image>

V. Potency and Efficacy

Potency describes the amount of drug required to produce a given effect and is quantified by the EC50 or ED50, with lower values indicating greater potency. A more potent drug produces the same effect as a less potent drug at a lower concentration or dose, reflected graphically as a leftward position on the dose-response curve. Potency is primarily a function of drug affinity for its receptor and the efficiency of receptor-effector coupling in the target tissue. While potency affects the dose administered, it generally has limited clinical significance when comparing drugs of the same class, as dosing can simply be adjusted to achieve equivalent effects. The primary clinical relevance of potency lies in practical considerations such as pill size, injection volume, and cost of goods rather than therapeutic outcome.

Efficacy represents the maximum response a drug can produce regardless of dose and is the more clinically important parameter when selecting among drugs in the same class. A drug with higher efficacy produces a greater maximum effect than one with lower efficacy, reflected as a higher plateau (Emax) on the dose-response curve. Efficacy is determined by the intrinsic activity of the drug at its receptor and the characteristics of the receptor-effector system, including receptor density and signal amplification mechanisms. Full agonists have higher efficacy than partial agonists at the same receptor, with the ceiling effect of partial agonists sometimes providing therapeutic advantages such as reduced toxicity. When treating severe conditions requiring maximum receptor activation, drugs with high efficacy are preferred; for conditions where moderate effect with safety margin is desired, partial agonists may be advantageous.

Comparing potency and efficacy between drugs reveals important distinctions for clinical decision-making and helps avoid common misconceptions. Morphine and fentanyl are both full opioid agonists with equal efficacy (same maximum analgesic effect), but fentanyl is approximately 100 times more potent (produces equivalent analgesia at 1/100th the dose). Conversely, morphine and buprenorphine have similar potency but different efficacy, with buprenorphine as a partial agonist producing lower maximum analgesia but also less respiratory depression. A highly potent drug is not necessarily better than a less potent drug if both have adequate efficacy and can be dosed appropriately. The choice between drugs should consider efficacy requirements for the clinical situation, safety profiles, pharmacokinetic properties, and practical factors including cost and available formulations.

The therapeutic index (TI) quantifies drug safety by comparing doses producing therapeutic and toxic effects in a population. Calculated as TI = TD50/ED50 (or LD50/ED50 in preclinical studies), higher values indicate a wider margin between effective and toxic doses. Drugs with high therapeutic indices, such as penicillin, can be dosed over a wide range with minimal toxicity risk, while drugs with low therapeutic indices like warfarin, lithium, and digoxin require careful dosing and monitoring. The therapeutic window, defined as the concentration range between minimum effective concentration and minimum toxic concentration, represents the clinical application of therapeutic index concepts. Narrow therapeutic window drugs require therapeutic drug monitoring to ensure levels remain within the safe and effective range, with frequent dose adjustments based on measured drug concentrations.

<image>Panel A: Potency comparison showing three drugs with identical efficacy but different EC50 values, demonstrating that potency relates to curve position on x-axis while efficacy relates to maximum height. Panel B: Efficacy comparison showing full agonist reaching 100% Emax versus partial agonist plateau at 60% Emax, with clinical implications for each (maximum effect versus ceiling safety). Panel C: Drug comparison matrix for opioids showing fentanyl (high potency, high efficacy), morphine (lower potency, high efficacy), and buprenorphine (moderate potency, lower efficacy) with clinical applications for each. Panel D: Therapeutic index diagram showing ED50 and TD50 on quantal dose-response curves, calculating TI, and illustrating narrow (warfarin) versus wide (penicillin) therapeutic windows with monitoring implications.</image>

VI. Receptor Regulation

Desensitization describes the diminished response to a drug despite continued or repeated exposure, occurring through rapid adaptive mechanisms at the receptor level. This process develops within minutes to hours of agonist exposure and represents a protective mechanism against overstimulation of signaling pathways. The molecular mechanisms of desensitization include receptor phosphorylation by G protein-coupled receptor kinases (GRKs) and second messenger-dependent kinases, which reduces receptor coupling to downstream signaling molecules. Phosphorylated receptors bind arrestin proteins that sterically block G protein coupling and target receptors for internalization via clathrin-coated pits. Tachyphylaxis represents rapid desensitization that occurs after only one or a few doses, as observed with indirect-acting sympathomimetics that deplete neurotransmitter stores.

Downregulation involves a reduction in the total number of receptors, occurring over a longer time course of hours to days during sustained agonist exposure. This process begins with receptor internalization following desensitization, but instead of recycling to the cell surface, internalized receptors are targeted to lysosomes for degradation. Additionally, chronic agonist exposure can reduce receptor gene transcription, decreasing the synthesis of new receptor proteins. The net result is fewer total receptors available for activation, requiring higher drug concentrations to achieve the same effect. Downregulation contributes to the tolerance observed with chronic use of many drugs including opioids, benzodiazepines, and beta-agonists, necessitating dose escalation to maintain therapeutic effect.

Upregulation represents the converse process in which receptor numbers increase in response to chronic antagonist exposure or reduced agonist stimulation. When receptors are chronically blocked by antagonists, compensatory mechanisms increase receptor gene transcription and decrease receptor degradation, resulting in higher receptor density. The clinical significance of upregulation becomes apparent when antagonist therapy is abruptly discontinued, as the supersensitive receptor population now responds excessively to normal agonist levels. Beta-blocker withdrawal syndrome exemplifies this phenomenon, where abrupt cessation after chronic therapy can precipitate rebound tachycardia, hypertension, and angina due to upregulated beta-adrenergic receptors responding to circulating catecholamines. Gradual tapering of antagonist doses allows time for receptor numbers to normalize and prevents withdrawal complications.

Tolerance represents the broader phenomenon of decreased drug effect with repeated administration, encompassing multiple mechanisms beyond receptor regulation. Pharmacodynamic tolerance results from the receptor desensitization and downregulation processes described above, reducing target tissue responsiveness. Pharmacokinetic tolerance occurs when repeated drug exposure induces metabolic enzymes, increasing drug clearance and reducing plasma concentrations at the same dose. Learned (behavioral) tolerance involves adaptive changes in behavior that compensate for drug effects, as seen with alcohol where experienced users function better at the same blood alcohol levels than naive users. Cross-tolerance occurs when tolerance to one drug confers reduced responsiveness to related drugs acting through the same mechanism, as observed among opioids and among benzodiazepines.

<image>Panel A: Desensitization mechanism showing agonist-activated GPCR being phosphorylated by GRK, beta-arrestin binding blocking G protein coupling, receptor internalization into endosome, and either recycling to surface or progression to downregulation. Panel B: Time course comparison of desensitization (minutes-hours), downregulation (hours-days), and tolerance development (days-weeks), with relative receptor responsiveness on y-axis during continuous agonist exposure. Panel C: Upregulation and withdrawal showing receptor density increasing during chronic antagonist treatment, then rebound hypersensitivity upon drug cessation with exaggerated response to normal agonist levels. Panel D: Types of tolerance illustrated showing pharmacodynamic (receptor changes), pharmacokinetic (enzyme induction increasing clearance), learned behavioral (compensatory adaptation), and cross-tolerance (shared mechanism between related drugs).</image>

VII. Signal Transduction

Second messengers are intracellular molecules that relay and amplify signals from cell surface receptors to effector proteins, translating extracellular stimuli into cellular responses. These small molecules or ions are generated or released in response to receptor activation and diffuse within the cytoplasm to activate downstream signaling proteins. Cyclic adenosine monophosphate (cAMP) is generated from ATP by adenylyl cyclase and activates protein kinase A (PKA) to phosphorylate numerous cellular targets. Cyclic guanosine monophosphate (cGMP) is produced by guanylyl cyclase and activates protein kinase G (PKG), with important roles in smooth muscle relaxation and visual transduction. Inositol trisphosphate (IP3) and diacylglycerol (DAG) are generated together by phospholipase C cleavage of membrane phospholipids, with IP3 releasing calcium from endoplasmic reticulum stores and DAG activating protein kinase C. Calcium ions themselves serve as second messengers, with cytoplasmic calcium elevation triggering diverse responses through calmodulin and other calcium-binding proteins.

The cAMP signaling pathway exemplifies second messenger cascades and is targeted by numerous drugs. Stimulatory G proteins (Gs) activate adenylyl cyclase upon receptor activation, converting ATP to cAMP and rapidly increasing intracellular cAMP concentrations. cAMP binds to the regulatory subunits of protein kinase A, releasing active catalytic subunits that phosphorylate serine and threonine residues on target proteins. Phosphorylation modifies the activity of enzymes, ion channels, and transcription factors, producing the cellular response to receptor activation. The signal is terminated by phosphodiesterases (PDEs) that hydrolyze cAMP to inactive AMP; sildenafil and related drugs inhibit PDE5, prolonging cGMP signaling in vascular smooth muscle. Inhibitory G proteins (Gi) reduce cAMP levels by inhibiting adenylyl cyclase, producing opposite effects to Gs-coupled receptor activation.

The phospholipase C (PLC) pathway activated by Gq-coupled receptors generates two second messengers with distinct downstream effects. Activated Gq stimulates phospholipase C to cleave membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and DAG. IP3 is water-soluble and diffuses to the endoplasmic reticulum, where it binds IP3 receptors that function as calcium channels, releasing stored calcium into the cytoplasm. The resulting elevation in cytoplasmic calcium activates calcium-dependent processes including muscle contraction, secretion, and enzyme activation. DAG remains membrane-associated and recruits and activates protein kinase C (PKC), which phosphorylates diverse substrate proteins. The PLC pathway is responsible for effects mediated by alpha-1 adrenergic agonists, muscarinic M1 and M3 agonists, and histamine H1 agonists.

Signal amplification is a fundamental property of second messenger cascades that enables small numbers of extracellular ligand molecules to produce large cellular responses. Each activated receptor can sequentially activate multiple G proteins during its active period, representing the first amplification step. Each active G protein stimulates an enzyme (adenylyl cyclase or phospholipase C) that catalytically produces many second messenger molecules. The second messengers activate protein kinases that each phosphorylate many substrate molecules, adding another amplification layer. This enzymatic cascade means that binding of a few agonist molecules to receptors can ultimately modify millions of downstream proteins. The amplification inherent in signal transduction explains why drugs can produce profound effects at very low concentrations and why receptors need not all be occupied to achieve maximum effect (receptor reserve or spare receptors).

<image>Panel A: Second messenger overview diagram showing cell surface receptor activating G protein, which activates effector enzyme (adenylyl cyclase or PLC), producing second messengers (cAMP, IP3, DAG, Ca2+) that activate protein kinases to phosphorylate cellular targets. Panel B: cAMP pathway detail showing Gs-coupled receptor activating adenylyl cyclase, cAMP generation, PKA activation with regulatory and catalytic subunit separation, target phosphorylation, and PDE termination (with PDE inhibitor drug target indicated). Panel C: PLC pathway showing Gq activation, PIP2 cleavage into IP3 and DAG, IP3-mediated calcium release from ER, and DAG activation of membrane-associated PKC, with downstream effects of each branch. Panel D: Signal amplification cascade showing quantitative amplification at each step: 1 receptor activating 100 G proteins, each activating enzyme producing 1000 second messengers, each activating kinase phosphorylating 1000 substrates, demonstrating million-fold amplification.</image>

VIII. Drug Interactions

Drug interactions occur when the presence of one drug alters the effect of another and can be classified as pharmacokinetic or pharmacodynamic based on the mechanism involved. Pharmacokinetic interactions affect drug absorption, distribution, metabolism, or excretion, altering drug concentrations at the site of action without changing the intrinsic response to a given concentration. Pharmacodynamic interactions occur when drugs affect the same physiological system, modifying the response to a given drug concentration through additive, synergistic, or antagonistic mechanisms. Many clinically significant interactions involve both pharmacokinetic and pharmacodynamic components, creating complex effects that require careful clinical management. Understanding interaction mechanisms allows prediction, prevention, and management of these effects in patients receiving multiple medications.

Pharmacokinetic interactions can occur at any step of drug disposition and may either increase or decrease drug concentrations. Absorption interactions occur when one drug alters the gastrointestinal absorption of another, as when antacids containing divalent cations (calcium, magnesium, aluminum) chelate fluoroquinolone antibiotics, reducing their absorption and efficacy. Distribution interactions occur when highly protein-bound drugs compete for binding sites, potentially displacing one another and transiently increasing free drug concentrations, though this mechanism is less clinically significant than once believed. Metabolism interactions are particularly important, involving enzyme induction (rifampin decreasing oral contraceptive efficacy) or inhibition (erythromycin increasing carbamazepine levels) as discussed in the pharmacokinetics lecture. Excretion interactions include competition for renal tubular secretion, as when probenecid blocks penicillin secretion to prolong its duration of action, and altered urinary pH affecting reabsorption of weak acids and bases.

Pharmacodynamic interactions describe altered drug effects when two drugs act on the same physiological system, characterized by the mathematical relationship between their combined effects. Additive interactions occur when the combined effect equals the sum of individual effects (1 + 1 = 2), as when two sedative drugs produce sedation equal to the sum of their individual sedative effects. Synergistic interactions produce combined effects greater than the sum of individual effects (1 + 1 > 2), potentially through complementary mechanisms; trimethoprim-sulfamethoxazole exhibits synergistic antibacterial activity by inhibiting sequential steps in folate synthesis. Antagonistic interactions occur when the combined effect is less than the sum (1 + 1 < 2), as when a beta-blocker attenuates the bronchodilating effect of a beta-agonist. Potentiation describes the special case where an inactive drug enhances the effect of an active drug, as seen with clavulanic acid (no antibacterial activity) inhibiting beta-lactamase to enhance amoxicillin efficacy.

Clinically important drug interactions require recognition and management to prevent adverse outcomes in patients. The combination of warfarin and aspirin increases bleeding risk through pharmacodynamic synergy, as warfarin inhibits coagulation factor synthesis while aspirin inhibits platelet function, requiring careful monitoring if combined. ACE inhibitors with potassium-sparing diuretics can cause dangerous hyperkalemia through additive effects on potassium retention. Monoamine oxidase inhibitors (MAOIs) with tyramine-rich foods or sympathomimetic drugs can precipitate hypertensive crisis due to impaired catecholamine metabolism and enhanced sympathetic activity. Serotonin syndrome results from combined use of multiple serotonergic drugs (SSRIs, MAOIs, tramadol, triptans), producing potentially life-threatening hyperthermia, neuromuscular abnormalities, and autonomic instability. Awareness of high-risk combinations and use of drug interaction checking tools are essential components of safe prescribing.

<image>Panel A: Classification diagram distinguishing pharmacokinetic interactions (affecting drug levels: absorption, distribution, metabolism, excretion examples) from pharmacodynamic interactions (affecting drug response: additive, synergistic, antagonistic). Panel B: Pharmacokinetic interaction examples showing fluoroquinolone chelation by antacid reducing absorption, CYP450 inhibition by erythromycin increasing substrate levels, and probenecid blocking penicillin tubular secretion. Panel C: Pharmacodynamic interaction types illustrated mathematically and graphically: additive (1+1=2), synergistic (1+1>2 with steeper combined curve), and antagonistic (1+1<2 with reduced combined effect). Panel D: High-risk clinical interactions showing warfarin + aspirin (bleeding), ACEI + K-sparing diuretic (hyperkalemia), MAOI + tyramine (hypertensive crisis), and multiple serotonergics (serotonin syndrome) with mechanisms and clinical manifestations.</image>

IX. Adverse Drug Reactions

Adverse drug reactions (ADRs) are harmful and unintended responses to medications that occur at doses normally used for prophylaxis, diagnosis, or treatment. ADRs represent a significant cause of morbidity and mortality, accounting for a substantial percentage of hospital admissions and contributing to healthcare costs. Classification systems categorize ADRs by mechanism, time course, and severity to facilitate understanding, prevention, and management. The most widely used classification distinguishes Type A (augmented) reactions that are predictable extensions of pharmacological effects from Type B (bizarre) reactions that are unpredictable and often immunologically mediated. Additional categories include Type C (chronic/cumulative), Type D (delayed effects such as carcinogenicity), and Type E (end-of-treatment withdrawal effects).

Type A reactions are the most common adverse drug reactions, representing exaggerated but otherwise normal pharmacological responses to the drug. These reactions are dose-dependent, predictable based on the drug's mechanism of action, and generally preventable with appropriate dosing. Examples include hypoglycemia from insulin or sulfonylureas, bleeding from anticoagulants, and bradycardia from beta-blockers, all representing excessive versions of the intended therapeutic effect. Type A reactions also include side effects that are predictable consequences of drug action on non-target tissues, such as dry mouth from anticholinergics or sedation from antihistamines. Prevention strategies focus on appropriate dose selection, identification of susceptible patients (elderly, organ dysfunction), and monitoring for early signs of excessive effect.

Type B reactions are unpredictable, not dose-related, and often immunologically mediated or due to genetic susceptibility. These reactions are less common than Type A but often more serious and not preventable through dose adjustment. Drug allergies represent a major category of Type B reactions, with penicillin allergy affecting approximately 10% of patients who report it (though true IgE-mediated allergy is less common upon testing). Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, potentially fatal Type B reactions characterized by mucocutaneous blistering and epidermal detachment, associated with sulfonamides, anticonvulsants, and allopurinol. Idiosyncratic reactions due to genetic polymorphisms include hemolytic anemia from oxidant drugs in G6PD-deficient patients and malignant hyperthermia from volatile anesthetics in susceptible individuals. Prevention of Type B reactions relies on identifying susceptible individuals through history, genetic testing where available, and avoiding causative agents.

Drug allergy mechanisms follow the Gell and Coombs classification of hypersensitivity reactions, with different time courses and clinical presentations. Type I (IgE-mediated) reactions develop within minutes of drug exposure and manifest as urticaria, angioedema, bronchospasm, or anaphylaxis; immediate reactions to penicillins and latex are classic examples. Type II (cytotoxic) reactions involve antibody-mediated cell destruction occurring over hours, as with drug-induced hemolytic anemia or thrombocytopenia. Type III (immune complex) reactions develop over days to weeks, causing serum sickness with fever, rash, arthralgia, and lymphadenopathy, historically associated with antitoxin serum and still seen with some monoclonal antibodies. Type IV (delayed) reactions are T-cell mediated, developing over days and presenting as contact dermatitis, maculopapular drug eruptions, or severe reactions like SJS/TEN and drug reaction with eosinophilia and systemic symptoms (DRESS). Recognition of reaction type guides management decisions including drug discontinuation, supportive care, and future drug avoidance.

<image>Panel A: ADR classification system showing Type A (augmented, predictable, dose-related), Type B (bizarre, unpredictable, not dose-related), Type C (chronic/cumulative), Type D (delayed carcinogenicity/teratogenicity), and Type E (end-of-treatment withdrawal) with examples of each. Panel B: Type A reaction mechanism showing dose-response curve with therapeutic effect and predictable toxicity at higher doses, with examples of hypoglycemia, bleeding, and sedation related to known pharmacology. Panel C: Type B reaction spectrum showing immunological (drug allergy, SJS/TEN) and genetic (G6PD deficiency, malignant hyperthermia) mechanisms, emphasizing unpredictability and need for individual susceptibility identification. Panel D: Drug allergy types showing Type I (immediate, IgE, minutes, anaphylaxis), Type II (cytotoxic, hours, hemolysis), Type III (immune complex, days, serum sickness), and Type IV (delayed, T-cell, days-weeks, SJS/TEN) with mechanisms and timing.</image>

X. Clinical Pharmacodynamic Concepts

The therapeutic window defines the range of drug concentrations that produce therapeutic effect without unacceptable toxicity, representing the practical application of therapeutic index concepts to individual patient dosing. Below the minimum effective concentration (MEC), drug levels are insufficient to produce the desired therapeutic effect, while above the minimum toxic concentration (MTC), adverse effects become unacceptable. A wide therapeutic window provides flexibility in dosing and reduces the need for precise titration or therapeutic drug monitoring. Drugs with narrow therapeutic windows, including lithium, digoxin, aminoglycosides, and anticonvulsants, require careful dosing and regular monitoring to maintain concentrations within the safe and effective range. Factors that alter drug pharmacokinetics (renal or hepatic impairment, drug interactions) can shift concentrations outside the therapeutic window, requiring dose adjustment.

Loading and maintenance dose concepts translate pharmacokinetic principles into clinical dosing strategies to achieve and maintain therapeutic drug concentrations. Loading doses are larger initial doses designed to rapidly achieve therapeutic concentrations, particularly important for drugs with long half-lives where waiting 4-5 half-lives for steady state would unacceptably delay therapy. The loading dose is calculated based on the target concentration and volume of distribution, accounting for the need to fill the entire distribution volume immediately. Maintenance doses replace drug eliminated during each dosing interval to maintain the average steady-state concentration, calculated based on clearance and desired concentration. For critical situations such as severe infections or status epilepticus, loading doses provide immediate therapeutic levels while maintenance doses sustain them; for chronic conditions with less urgency, treatment may begin with maintenance doses alone.

Drug selectivity describes the relative effects of a drug on different receptor subtypes or targets and directly impacts the balance between therapeutic effects and adverse effects. Selective drugs preferentially interact with one receptor subtype or target, producing more specific effects with fewer off-target adverse effects. Beta-1 selective antagonists like metoprolol preferentially block cardiac beta-1 receptors over bronchial beta-2 receptors, reducing bronchospasm risk compared to non-selective beta-blockers. However, selectivity is typically relative rather than absolute and is often dose-dependent, with higher doses producing effects at additional receptor subtypes. Receptor selectivity must be distinguished from tissue selectivity, which results from differences in receptor expression between tissues rather than receptor-drug affinity differences. Drug development increasingly targets selective agents to maximize therapeutic benefit while minimizing adverse effects.

Spare receptors (receptor reserve) describe the phenomenon in which maximum biological response can be achieved without full receptor occupancy, with important implications for drug action. This occurs when signal amplification through second messenger cascades allows partial receptor activation to produce maximum effector response. The existence of spare receptors means that drugs can produce full effects at concentrations well below those needed for complete receptor occupation, increasing sensitivity to low drug concentrations. Receptor reserve provides a safety margin, as receptor downregulation or antagonist presence still allows maximum response if sufficient receptors remain. Tissues with large receptor reserve are more sensitive to agonists and more difficult to fully antagonize. Understanding spare receptor concepts helps explain why threshold doses can produce measurable effects, why partial agonists have efficacy greater than their receptor occupancy, and why receptor downregulation may not immediately reduce drug effectiveness.

<image>Panel A: Therapeutic window diagram showing plasma concentration over time with minimum effective concentration (MEC) and minimum toxic concentration (MTC) defining the therapeutic range, with comparison of wide versus narrow therapeutic windows. Panel B: Loading and maintenance dose strategy showing concentration-time curve with loading dose achieving immediate therapeutic level versus gradual accumulation with maintenance doses alone, with formulas for calculating each. Panel C: Drug selectivity spectrum showing highly selective beta-1 blocker acting predominantly on cardiac receptors versus non-selective beta-blocker affecting both cardiac and bronchial receptors, with clinical implications of each approach. Panel D: Spare receptor concept showing only 20% receptor occupancy needed for 100% response due to signal amplification, with implications for drug sensitivity, safety margin during downregulation, and partial agonist behavior.</image>

Summary

• Pharmacodynamics describes what drugs do to the body through interactions with receptors, enzymes, ion channels, and other molecular targets
• Receptor types include GPCRs (most common drug targets), ligand-gated ion channels (fastest response), receptor tyrosine kinases, and nuclear receptors (slowest, gene transcription)
• GPCR signaling occurs through Gs (increases cAMP), Gi (decreases cAMP), and Gq (increases IP3/DAG and calcium)
• Dose-response relationships are characterized as graded (effect magnitude) or quantal (population responding)
• Potency reflects the dose required for effect (EC50), while efficacy represents maximum achievable effect (Emax)
• Full agonists produce maximum response, partial agonists produce submaximal response, and antagonists block agonist effects without activating receptors
• Competitive antagonists cause rightward shift with preserved Emax; non-competitive antagonists reduce Emax
• Therapeutic index (TI = TD50/ED50) measures drug safety, with higher values indicating wider safety margins
• Receptor regulation includes desensitization (rapid), downregulation (slower), and upregulation (during antagonist withdrawal), all contributing to tolerance
• Adverse drug reactions are classified as Type A (predictable, dose-related) or Type B (idiosyncratic, often immunologic)

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown